Literature DB >> 29715081

Estimation of Risk of Normal-tissue Toxicity Following Gastric Cancer Radiotherapy with Photon- or Scanned Proton-beams.

Gracinda Mondlane1,2, Ana Ureba3, Michael Gubanski4, Pehr A Lind5,6, Albert Siegbahn5,6.   

Abstract

BACKGROUND/AIM: Gastric cancer (GC) radiotherapy involves irradiation of large tumour volumes located in the proximities of critical structures. The advantageous dose distributions produced by scanned-proton beams could reduce the irradiated volumes of the organs at risk (OARs). However, treatment-induced side-effects may still appear. The aim of this study was to estimate the normal tissue complication probability (NTCP) following proton therapy of GC, compared to photon radiotherapy. PATIENTS AND METHODS: Eight GC patients, previously treated with volumetric-modulated arc therapy (VMAT), were retrospectively planned with scanned proton beams carried out with the single-field uniform-dose (SFUD) method. A beam-specific planning target volume was used for spot positioning and a clinical target volume (CTV) based robust optimisation was performed considering setup- and range-uncertainties. The dosimetric and NTCP values obtained with the VMAT and SFUD plans were compared.
RESULTS: With SFUD, lower or similar dose-volume values were obtained for OARs, compared to VMAT. NTCP values of 0% were determined with the VMAT and SFUD plans for all OARs (p>0.05), except for the left kidney (p<0.05), for which lower toxicity was estimated with SFUD.
CONCLUSION: The NTCP reduction, determined for the left kidney with SFUD, can be of clinical relevance for preserving renal function after radiotherapy of GC. Copyright
© 2018, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.

Entities:  

Keywords:  NTCP; SFUD; VMAT; gastric cancer; treatment planning

Mesh:

Year:  2018        PMID: 29715081     DOI: 10.21873/anticanres.12503

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  4 in total

1.  Salvage Photon or Proton Radiotherapy for Oligo-recurrence in Regional Lymph Nodes After Surgery for Non-small Cell Lung Cancer.

Authors:  Masatoshi Nakamura; Kayoko Ohnishi; Hitoshi Ishikawa; Kensuke Nakazawa; Toshihiro Shiozawa; Toshiyuki Okumura; Ikuo Sekine; Yukio Sato; Nobuyuki Hizawa; Hideyuki Sakurai
Journal:  In Vivo       Date:  2020 Jul-Aug       Impact factor: 2.155

Review 2.  Proton Therapy in the Management of Luminal Gastrointestinal Cancers: Esophagus, Stomach, and Anorectum.

Authors:  Jana M Kobeissi; Charles B Simone; Lara Hilal; Abraham J Wu; Haibo Lin; Christopher H Crane; Carla Hajj
Journal:  Cancers (Basel)       Date:  2022-06-10       Impact factor: 6.575

3.  The Potential Role of Intensity-Modulated Proton Therapy in Hepatic Carcinoma in Mitigating the Risk of Dose De-Escalation.

Authors:  Luca Cozzi; Tiziana Comito; Mauro Loi; Antonella Fogliata; Ciro Franzese; Davide Franceschini; Elena Clerici; Giacomo Reggiori; Stefano Tomatis; Marta Scorsetti
Journal:  Technol Cancer Res Treat       Date:  2020 Jan-Dec

Review 4.  A scoping review of patient selection methods for proton therapy.

Authors:  Nicole Zientara; Eileen Giles; Hien Le; Michala Short
Journal:  J Med Radiat Sci       Date:  2021-09-02
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.